Medical | Page 360 of 472 | SpiritIndia.com

Health :: Abbott to Expand Presence in Lipid Management Market with Acquisition of Kos Pharmaceuticals

Abbott and Kos Pharmaceuticals, Inc. today announced a definitive agreement for Abbott to acquire Kos for $78 per share in cash, for a total transaction value of $3.7 billion, net of cash currently held by Kos. Based in Cranbury, N.J., Kos is a specialty pharmaceutical company that develops and markets proprietary medications for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company has a growing presence in the $20 billion lipid management market.

Pharmacy :: Elan Announces Proposed Offering of Senior Notes

Elan Corporation, plc (“Elan”) today announced that its wholly owned subsidiaries, Elan Finance public limited company and Elan Finance Corp., intend to offer, subject to market conditions, US$500 million in aggregate principal amount of senior fixed rate notes due 2013 and senior floating rate notes due 2013. The notes will be offered in the United States, only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and to non-U.S. persons in accordance with Regulation S under the Securities Act.

Restless Legs Syndrome :: Boehringer Ingelheim?s pramipexole for the treatment of Restless Legs Syndrome RLS

Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved pramipexole, a non-ergot dopamine agonist, for the treatment of moderate to severe primary Restless Legs Syndrome (RLS).1 This is an important milestone for pramipexole (Mirapexin? / Sifrol? / Mirapex?), which was already approved throughout the European Union in April 2006 for this second indication.

Rheumatoid Arthritis :: ORENCIA, abatacept demonstrate continued efficacy in adults with rheumatoid arthritis

Bristol-Myers Squibb Company (NYSE: BMY) today announced that two-year data from three Phase III pivotal trials demonstrate the long-term efficacy of ORENCIA? (abatacept) in adult patients with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate and TNF antagonists. The data also demonstrate that ORENCIA provided clinically meaningful improvements in multiple aspects of health-related quality of life and physical function, sustained improvements in pain and had a consistent safety and tolerability profile through two years of treatment. These data will be presented at the upcoming 2006 American College of Rheumatology (ACR) Annual Scientific Meeting.

Heart Disease :: Systolic Blood Pressure Predicts Mortality in Heart Failure Patients

Systolic blood pressure, a readily available vital sign taken at hospital admission, has been found to be a key factor in predicting mortality risk and revealing important disease characteristics for heart failure patients, according to a team of academic researchers.

Google :: Doctors get Google’s help in diagnosis of difficult cases

Doctors in doubt about a patient’s ailment could use Google to help them reach a diagnosis, researchers said today. A new Australian study recommends doctors use Google to help diagnose difficult cases, despite indications it’s only 60 per cent accurate. Specialists at Princess Alexandra Hospital in Brisbane studied how effective the world’s largest and most popular search engine is for helping diagnose rare diseases.

Breast Cancer :: Surgical biopsy may reveal cancer in women with rare but benign breast condition

A study at Washington University School of Medicine in St. Louis showed that in women whose initial breast biopsies revealed certain rare, yet benign breast conditions, more extensive follow-up surgical biopsies found cancer up to 25 percent of the time. Most of the cancers were invasive, meaning the tumors had penetrated normal breast tissue and would require treatment.

Cancer :: Patients respond well to first study to test higher doses of an anti-cancer drug

Researchers in the UK and the United States have found that a drug composed of an antibody carrying a highly toxic anti-cancer agent is well tolerated by patients at much higher doses than have been used before, according to research presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Prague on Friday.

Bladder Cancer :: Children’s exposure to smoking cigarettes linked to bladder cancer – UK

Children and adolescents may be even more susceptible to the harmful effects of tobacco smoke than adults – according to new research into bladder cancer published in next week?s edition of the International Journal of Cancer*.

Diagnosis :: Try Google’s medical diagnosis for rare diseases – BMJ

A new Australian study recommends doctors use Google to help diagnose difficult cases, despite indications it’s only 60 per cent accurate. Specialists at Princess Alexandra Hospital in Brisbane studied how effective the world’s largest and most popular search engine is for helping diagnose rare diseases.